So why would these drug companies push drugs so hard if they don’t claim their effectiveness? Fame and market share — and the ability to sell other drugs if Covid is in control. “As long as these drugs are available in India, China and sub-Saharan Africa, Pfizer can sell whatever drugs they want to sell,” Iyer said. “Hospitals can absorb cancer patients or absorb them with other drugs. And fortunately, it helps a lot. “
To put it bluntly, none of this means that the drug has any effect. It is likely that Paxlovid, for example, shrinks over 89 percent of the time. David Boulevard, an infectious disease physician at the University of Minnesota, said, “If these drugs are used on hospital patients 10 days after they become ill, they will not have much effect.” Multiple covid drug trials. For one thing, people need to get tested for Covid before they get their prescription. “It’s complicated. It’s hard. In a low-income country, it is easy for people to be vaccinated. If you can vaccinate high-risk people, it’s much better than trying to deal with both diagnosis and treatment. “
There are also complications with the actual use of both drugs. Molnupiravi has been kicking for almost 20 years, and it has been noticed in various diseases. Mills said most virologists were frustrated with the actual use of it – in part because of mutagenicity problems that researchers have seen in years of analysis and testing. It probably won’t be used in pregnant or pregnant women, for example. Recent Articles Inside Statistics Says that no problem was found in the animal test of Mark of Malnupiravir, and Statistics A Merck executive quotes VP as telling investors that the company has “confidence” in the drug’s safety profile.
Ritonavir, that second component of the Pfizer package, not only inhibits liver activity; It has well-known interactions with anticoagulant drugs and widely prescribed anticoagulant drugs. So those who take them may have to change their dosage, or stop taking them for five days of the whole course. Not impossible, but not easy either.
That said, many researchers and public health experts believe the new drugs will help. Mills even said he thinks they will be affected, although it’s hard to say how big it is. And the total absence of deaths in the Paxlovid trial could be surprising, if the pattern is above a few thousand people. “I am very optimistic here,” said Tulio de Oliveira, director of the KwaZulu-Natal Research and Innovation Sequencing Platform at KwaZulu-Natal University in South Africa. “The companies, Mark and Pfizer, have issued clear guidelines that drug prices will be much lower in developing countries. In addition, they are already involved with a number of local pharmaceutical companies in the developing world. ”
The flip side of the big pharma companies having to justify their huge pre-orders to the governments is that the governments have already seen more information than the companies have disclosed. “They both have trials. “They’ve seen data we don’t have,” said Eric Topol, director of the Scripps Research Translational Institute. “They looked outside the press release and, as you can see, bought a few million doses of the two pills.” To Topol, who is tracking efforts to develop vaccines and drugs across the epidemic, suggests that unpublished data looks as good as the population.